Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination

Springer Science and Business Media LLC - Tập 54 - Trang 263-266 - 2011
Zhan Wang1, SongMei Yang1, Ling Zhou1, HaiJun Du1, WuNing Mo2, Yi Zeng1
1State Key Laboratory for Infectious Disease Prevention and Control, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
2Laboratory Department, The First Affiliated Hospital, Guangxi Medical University, Nanning, China

Tóm tắt

Cellular immune responses, particularly those associated with CD3+CD8+ cytotoxic T lymphocytes (CTL), are critical factors in controlling viral infection. Nasopharyngeal carcinoma (NPC) is closely associated with persistent Epstein-Barr virus (EBV) infection. NPC vaccine studies have focused on enhancing specific antiviral CTL responses. In this study, three vaccines capable of expressing the EBV-latent membrane protein 2 (LMP2) (a DNA vector, an adeno-associated virus (AAV) vector, and a replication-defective adenovirus serotype 5 (Ad5) vector) were respectively used to immunize female Balb/c mice (4–6 weeks old) at weeks 0, 2 and 4, either alone or in combination. Our results suggest that combined immunization with DNA, AAV, and adenovirus vector vaccines induced specific cellular immunity more effectively than any of these vectors alone or a combination of two of the three, constituting a sound vaccine strategy for the prevention and treatment of NPC.

Tài liệu tham khảo

Chan A T, Toe P M, Johnson P J. Nasopharyngeal carcinoma. Ann Oncol, 2002, 13: 1007–1025, 12176778, 10.1093/annonc/mdf179, 1:STN:280:DC%2BD38vitFWgtg%3D%3D Yu M C. Nasopharyngeal carcinoma: Epidemiology and dietary factors. IARC Sci Publ, 1991, 105: 39–47, 1855886 Taylor G S. T cell-based therapies for EBV-associated malignancies. Expert Opin Biol Ther, 2004, 4: 11–21, 14680465, 10.1517/14712598.4.1.11, 1:CAS:528:DC%2BD3sXpvVeqt7g%3D Lennette E T, Winberg G, Yadav M, et al. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer, 1995, 31A: 1875–1878, 8541116, 10.1016/0959-8049(95)00354-L, 1:STN:280:DyaK287jvVWisA%3D%3D Lee S P, Tierney R J, Thomas W A, et al. Conserved CTL epitopes within EBV latent membrane protein 2: A potential target for CTL-based tumor therapy. J Immunol, 1997, 158: 3325–3334, 9120290, 1:CAS:528:DyaK2sXit1Clt70%3D Lee S P, Chan A T, Cheung S T, et al. CTL control of EBV in nasopharyngeal carcinoma: EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol, 2000, 165: 573–582, 10861098, 1:CAS:528:DC%2BD3cXksVKltb4%3D Konishi K, Maruo S, Kato H, et al. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol, 2001, 82: 1451–1456, 11369890, 1:CAS:528:DC%2BD3MXkt1ChtrY%3D Straathof K C, Leen A M, Buza E L, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol, 2005, 175: 4137–4147, 16148164, 1:CAS:528:DC%2BD2MXpslClt70%3D Rooney C M, Smith C A, Ng C Y, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus related lympholiferation. Lancet, 1995, 345: 9–13, 7799740, 10.1016/S0140-6736(95)91150-2, 1:STN:280:DyaK2M%2FpslOgsA%3D%3D Zuo J M, Zhou L, Wang Q, et al. The in vitro and in vivo immunogenicity of recombination adenovirus vaccine containing EBV-latent membrane protein 2. Chin J Microbiol Immunol, 2003, 23: 446–449, 1:CAS:528:DC%2BD2cXktVSktb8%3D Ghosh S S, Gopinath P, Ramesh A. Adenoviral vectors: A promising tool for gene therapy. Appl Biotechnol, 2006, 133: 9–29, 10.1385/ABAB:133:1:9, 1:CAS:528:DC%2BD28Xjs1Wjsb4%3D Excler J L, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS, 1997, 11: S127–137, 9451976 Donnelly J J, Ulmer J B, Shiver J W. DNA vaccines. Annu Rev Immunol, 1997, 15: 617–648, 9143702, 10.1146/annurev.immunol.15.1.617, 1:CAS:528:DyaK2sXisVCmtLs%3D Li C, Bowles D E, Dyke T V. Adeno-associated virus vectors: Potential applications for cancer gene therapy. Cancer Gene Ther, 2005, 12: 913–925, 15962012, 10.1038/sj.cgt.7700876, 1:CAS:528:DC%2BD2MXht1Smur%2FE Excler J L. AIDS vaccine development: Perspectives, challenges & hopes. Indian J Med Res, 2005, 121: 568–581, 15817964, 1:CAS:528:DC%2BD2MXltVSqtLc%3D Casimiro D R, Chen L, Fu T M. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol, 2003, 77: 6305–6313, 12743287, 10.1128/JVI.77.11.6305-6313.2003, 1:CAS:528:DC%2BD3sXktV2nsrw%3D Xin K Q, Jounai N, Someya K. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther, 2005, 12: 1769–1777, 16079886, 10.1038/sj.gt.3302590, 1:CAS:528:DC%2BD2MXht1Oqt7rL Ponnazhagan S. Adenoassociated virus vectors for genetic immunization. Immunol Res, 2002, 26: 247–253, 12403362, 10.1385/IR:26:1-3:247, 1:CAS:528:DC%2BD38Xos1Cis7Y%3D Nikitina E Y, Chada S, Muro-Cacho C. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther, 2002, 9: 345–352, 11938454, 10.1038/sj.gt.3301670, 1:CAS:528:DC%2BD38XisFGnsrc%3D
Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 54

263-266

Thông tin tác giả